Clinical trial of indomethacin in alzheimer’s disease

J. Rogers; L. C. Kirby; S. R. Hempelman; D. L. Berry; P. L. McGeer; A. W. Kaszniak; J. Zalinski; M. Cofield; L. Mansukhani; P. Willson; F. Kogan

doi:10.1212/wnl.43.8.1609

Clinical trial of indomethacin in alzheimer’s disease

J. Rogers
, L. C. Kirby
, S. R. Hempelman
, D. L. Berry
, P. L. McGeer
, A. W. Kaszniak
, J. Zalinski
, M. Cofield
, L. Mansukhani
, P. Willson
, F. Kogan

Psychology

Research output: Contribution to journal › Article › peer-review

1014 Scopus citations

Abstract

In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer’s disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.

Original language	English (US)
Pages (from-to)	1609-1611
Number of pages	3
Journal	Neurology
Volume	43
Issue number	8
DOIs	https://doi.org/10.1212/wnl.43.8.1609
State	Published - Aug 1993

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/wnl.43.8.1609

Cite this

@article{3488c5dc77dd4ed2900bdf0e363bc47c,

title = "Clinical trial of indomethacin in alzheimer{\textquoteright}s disease",

abstract = "In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer{\textquoteright}s disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3\% (±1.8\%), whereas placebo patients declined 8.4\% (±2.3\%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.",

author = "J. Rogers and Kirby, \{L. C.\} and Hempelman, \{S. R.\} and Berry, \{D. L.\} and McGeer, \{P. L.\} and Kaszniak, \{A. W.\} and J. Zalinski and M. Cofield and L. Mansukhani and P. Willson and F. Kogan",

year = "1993",

month = aug,

doi = "10.1212/wnl.43.8.1609",

language = "English (US)",

volume = "43",

pages = "1609--1611",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Clinical trial of indomethacin in alzheimer’s disease

AU - Rogers, J.

AU - Kirby, L. C.

AU - Hempelman, S. R.

AU - Berry, D. L.

AU - McGeer, P. L.

AU - Kaszniak, A. W.

AU - Zalinski, J.

AU - Cofield, M.

AU - Mansukhani, L.

AU - Willson, P.

AU - Kogan, F.

PY - 1993/8

Y1 - 1993/8

N2 - In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer’s disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.

AB - In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer’s disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.

UR - https://www.scopus.com/pages/publications/0027268393

UR - https://www.scopus.com/pages/publications/0027268393#tab=citedBy

U2 - 10.1212/wnl.43.8.1609

DO - 10.1212/wnl.43.8.1609

M3 - Article

C2 - 8351023

AN - SCOPUS:0027268393

SN - 0028-3878

VL - 43

SP - 1609

EP - 1611

JO - Neurology

JF - Neurology

IS - 8

ER -

Clinical trial of indomethacin in alzheimer’s disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this